Biopharmas raising money in public or private financings, including: 89bio, Antabio, Bicara, Carmot, Coya, Freya, OM, Roche, Shinobi.

Med-tech firms raising money in public or private financings, including: GE Healthcare, Laza Medical, Purehealth.

Biopharmas in Asia-Pacific raising money in public or private financings: Kazia, Rxcell.

Biopharmas raising money in public or private financings, including: Eyepoint, Immunoprecise, In8bio, Prelude, Springworks, Zafrens.

Med-tech firms raising money in public or private financings, including: Carebrook, Carthera, Milestone, Quest, Universal Diagnostics.

Following a strategic transaction with Graphite Bio Inc., Kamau Therapeutics is emerging from stealth with sickle cell treatment nulabeglogene autogedtemcel (nula-cel). Kamau received an option to acquire all of Graphite’s genome editing assets, including a platform technology that integrates precision DNA repair using homology directed repair and CRISPR/Cas9, as well as the autologous CRISPR/Cas9 gene corrected CD34+ cell product nula-cel, which offers a potential cure for sickle cell disease derived from the patient's cells.

Biopharmas raising money in public or private financings, including: Biosenic, Medsenic, Spyre.

Med-tech firms raising money in public or private financings, including: Cortex.